Expert Highlights Low Complications, Positive Cosmetic Outcomes in Breast Conservation Therapy for Multiple Ipsilateral Breast Cancer

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota discusses the incidence of complications and patient-reported outcomes associated with breast conservation therapy for multiple ipsilateral breast cancer.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Judy C. Boughey, MD, about safety data and patient reported outcomes following breast conservation therapy in patients with multiple ipsilateral breast cancer in the phase 2 ACOSOG Z11102 (Alliance) trial (NCT01556243).

According to Boughey, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, results from the trial highlighted low rates of complications related to breast-conserving surgery such as the development of a hematoma. She also described some of the positive cosmetic outcomes reported among patients who have received the procedure.

Transcript:

Generally, breast conserving therapy is a well-accepted procedure [and] has relatively low morbidity. Complications in terms of general breast-conserving therapy would either be a development of a hematoma or a seroma, but we had relatively acceptable and low rates of any complications related to breast conserving surgery.

The other aspect of breast-conserving therapy, which is the radiation to the whole breast and this particular protocol required radiation boosts to each of the lumpectomy sites. We previously published that the actual cosmetic outcomes on these patients were very good. The patient-reported outcome at 2 years was good or excellent in over 70% of the patients.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.